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ABSTRACT 
 
Canagliflozin, dapagliflozin and empagliflozin, all recently approved for treatment of Type 2 diabetes, 
were derived from the natural product phlorizin. They reduce hyperglycemia by inhibiting glucose re- 
uptake by SGLT2 in the kidney, without affecting intestinal glucose uptake by SGLT1. We now report 
that canagliflozin also activates AMP-activated protein kinase (AMPK), an effect also seen with 
phloretin (the aglycone breakdown product of phlorizin), but not to any significant extent with 
dapagliflozin, empagliflozin or phlorizin. AMPK activation occurred at canagliflozin concentrations 
measured in human plasma in clinical trials, and was caused by inhibition of Complex I of the 
respiratory chain, leading to increases in cellular AMP or ADP. Although canagliflozin also inhibited 
cellular glucose uptake independently of SGLT2, this did not account for AMPK activation. 
Canagliflozin also inhibited lipid synthesis, an effect that was absent in AMPK knockout cells and that 
required phosphorylation of ACC1 and/or ACC2 at the AMPK sites. Oral administration of 
canagliflozin activated AMPK in mouse liver, although not in muscle, adipose tissue or spleen. As 
phosphorylation of acetyl-CoA carboxylase by AMPK is known to lower liver lipid content, these data 
suggest a potential additional benefit of canagliflozin therapy compared to other SGLT2 inhibitors. 
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A recently introduced approach to treatment of Type 2 diabetes is selective inhibition of 
sodium/glucose cotransporter-2 (SGLT2) (1). SGLT1 and SGLT2 are related transporters that carry 
glucose across apical membranes of polarized epithelial cells against concentration gradients, driven by 
Na
+ 
gradients. SGLT1 is expressed in small intestine and responsible for most glucose uptake across 
the brush border membrane of enterocytes, while SGLT2 is expressed in kidney and responsible for 
most glucose readsorption in the convoluted proximal tubules. The first identified SGLT inhibitor was 
a natural product, phlorizin, which is broken down in the small intestine to the aglycone form, phloretin 
(Fig. 1). Although phlorizin had beneficial effects in hyperglycemia animals (2), it inhibits both SGLT1 
and SGLT2, causing gastrointestinal side-effects (3). This led to development of the synthetic analogs 
canagliflozin (4), dapagliflozin (5) and empagliflozin (6) (Fig. 1), which have 260-fold, 1100-fold and 
2,700-fold selectivity for SGLT2 over SGLT1, respectively (6). In meta-analyses of clinical trials in 
Type 2 diabetes, canagliflozin (7), dapagliflozin (8) or empagliflozin (9), either as monotherapy or 
combined with existing therapies, all reduced fasting plasma glucose, HbA1C and body weight, while 
canagliflozin also decreased plasma triglycerides (7). 
The current front-line therapy for Type 2 diabetes is metformin, a biguanide that lowers plasma 
glucose primarily by reducing hepatic glucose production (10). Metformin, and the related biguanide 
phenformin, inhibit complex I of the respiratory chain (11; 12), and activate the cellular energy sensor, 
AMP-activated protein kinase (AMPK) (13; 14). Binding to the AMPK-subunit of AMP and/or ADP, 
which are elevated during cellular energy stress, causes conformational changes that activate the kinase 
via allosteric effects and promotion of net phosphorylation of Thr172 on the AMPK-subunit (15-18). 
Metformin and phenformin increase ADP:ATP ratios, and fail to activate AMPK containing a subunit 
mutant that does not bind AMP/ADP (19), confirming that their AMPK-activating effects are mediated 
by increases in AMP/ADP. Once activated, AMPK acts to restore energy homeostasis by promoting 
catabolic pathways including fatty acid oxidation, while inhibiting anabolic pathways incuding fatty 
acid synthesis (15; 16). Its opposing acute effects on fat synthesis and oxidation are due to 
phosphorylation of two acetyl-CoA carboxylase isoforms, ACC1 and ACC2. There has been 
controversy as to whether AMPK explains all therapeutic benefits of metformin, because its acute 
effects on hepatic glucose production in mice were reported to be AMPK-independent (20; 21). 
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However, studies using knock-in mice, in which both ACC isoforms were replaced by mutants lacking 
the critical AMPK phosphorylation sites, suggested that the longer-term insulin-sensitizing effects of 
metformin are accounted for by phosphorylation and inactivation of ACC1/ACC2 by AMPK (22). 
We now report that canagliflozin activates AMPK, in intact cells and in vivo, by a mechanism 
involving inhibition of respiratory chain Complex I. Our results raise the possibility that some 
therapeutic benefits of canagliflozin might occur via AMPK activation rather than SGLT2 inhibition. 
RESEARCH DESIGN AND METHODS 
Materials and antibodies. Canagliflozin, dapagliflozin and empagliflozin were from Selleckchem; 
phlorizin, phloretin, metformin, phenformin, AICAR and 2-dinitrophenol from Sigma. A769662 was 
synthesized as described (23). Antibodies against phospho-Thr172 on AMPK-(pT172, #2531) were 
from Cell Signaling Technology. In Fig. 8, antibodies against phospho-ACC (pACC, #3661) and total 
ACC (#3676) were from Cell Signaling Technology. In other Figures, total ACC was detected using 
streptavidin directly conjugated to 800 nm flourophore (Rockland immunochemicals), and pACC (14) 
and total AMPK- (24) antibodies were as previously described. Anti-GLUT1 (#325510) was from 
Abcam and anti-SGLT2 (sc-47402) from Santa Cruz. 
Cell culture and lysis. HEK-293 cells, and wild type and AMPK knockout mouse embryo fibroblasts 
(MEFs) (25), were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 25 mmol/l glucose 
and 10% FBS; cell lysates were prepared as described previously (19). For Western blots shown in Fig. 
6C, tissues were homogenised in 5 vols of HES buffer (20 mmol/l Na Hepes, pH 7.4, 250 mmol/l 
sucrose, 1 mmol/l EDTA, Roche complete protease inhibitor cocktail) with a Dounce homogeniser and 
centrifuged (7,050 g, 20 min, 4
o
C). The pellet was resuspended in HES buffer and layered on top of 
buffer containing 1.12 mol/l sucrose, prior to centrifugation in a swing-out rotor (41,500 g, 60 min, 
4
o
C). Membranes were collected from the interface of the sucrose layers, diluted in HES buffer and 
centrifuged (150,000 g, 60 min, 4
o
C). The resultant plasma membrane-rich pellets were resuspended in 
HES buffer (0.2-0.4 ml). 
 
Immunoprecipitate   kinase   assays   and   other   analyses.   Methods   for   AMPK   assay   in 
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immunoprecipitates, SDS-PAGE, Western blotting, and determination of cellular ADP:ATP ratios and 
oxygen consumption in HEK-293 cells were described previously (19). Lipid synthesis in MEFs was 
analysed by starving cells of serum for 3 hr then treating with drug or vehicle in the presence of [14C] 
acetate (1mCi/ml)/0.4 mmol/l Na acetate for 3 hr. Cells washed with PBS prior to extraction to 
determine incorporation of label into total lipid (26). Fatty acid oxidation was measured as etomoxir- 
sensitive 3H O production from [3H]palmitate. MEFs were preincubated with AMPK activators for 30 
min prior to incubation in [3H]palmitic acid (8 μCi/ml, 110 μmol/l), carnitine (50 μmol/l), fatty acid- 
free bovine serum albumin (0.5 mg/mL) in Earle’s-Hepes (116 mmol/l NaCl, 5.3 mmol/l KCl, 0.8 
mmol/l MgSO4, 1.8 mmol/l CaCl2, 1 mmol/l NaH2PO4, 20 mmol/l Hepes-NaOH, pH 7.4) in the 
presence or absence of etomoxir (50 μmol/l) for 90 min at 37°C; 3H O generated was separated and 
quantified as described (27). 
 
Animal experiments. All animal procedures were approved by the McMaster University Animal 
Ethics Research Board. Male and female mice (16-20 week), either wild-type or ACC1/ACC2 
(S79A/S212A) double knock-in (DKI), were housed in a pathogen-free facility under a 12 hr light/dark 
cycle at 23°C, with ad libitum access to standard chow and water. Primary hepatocytes were generated 
from wild type and DKI mice and the following day were treated for 4 hr with canagliflozin or vehicle 
before assessing AMPK and ACC phosphorylation and lipid synthesis, as described (22; 28). For 
experiments to examine AMPK and ACC phosphorylation in vivo, canagliflozin or vehicle (saline 
solution containing 0.5% carboxymethyl cellulose, 0.025% Tween-20) was administered by oral gavage 
(100 mg/kg, 10 µl/g). Mice were anaesthetized and tissues snap frozen in situ as previously described 
(22). Measurements of respiratory exchange ratio were performed in metabolic cages using a protocol 
(29) in which mice were fasted overnight and refed with chow for 2 hr before being gavaged with 
canagliflozin or vehicle as the time of food withdrawal In separate experiments, mice were treated 
as above, blood collected from a nick in the tail and glucose measured using a Roche glucometer. 
 
Measurements of oxygen uptake/respiration in primary mouse hepatocytes. Mitochondrial 
respiration  was  measured  by  high-resolution  respirometry  (Oroboros  Oxygraph-2  k,  Innsbruck, 
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Austria) at 37°C and room air-saturated O2 tension in respiration buffer (MIRO5) containing EGTA 
(0.5 mmol/l), MgCl2 (3 mmol/l), K-lactobionate (60 mmol/l), KH2PO4 (10 mmol/l), HEPES (20 mmol/l), 
sucrose (110 mmol/l) and fatty acid free BSA (1 g/l). Primary hepatocytes from wild type 
mice were generated as described above. The following day they were suspended in 2 ml of respiration 
buffer and 800 µl of the suspension added to respiration chambers. Digitonin (8.1 µmol/l) was added to 
permeabilize the cells, and 5 min later the assay was initiated. To measure Complex I-supported 
respiration, glutamate (5 mmol/l), malate (2 mmol/l) and ADP (2.5 mmol/l) were added and respiration 
allowed to reach steady state. To measure Complex II-supported respiration, rotenone (1.25 μmol/l), 
succinate (10 mmol/l) and ADP (2.5 mmol/l) were added and respiration allowed to reach steady state. 
Drugs were then added to respiring cells at the indicated concentrations. 
 
Measurements of glucose uptake. Cells were incubated in glucose-free Krebs-Ringer phosphate for 2 
hr, with AICAR present for the last 1 hr or canagliflozin/dapagliflozin for the last 15 min. 2- 
deoxyglucose (50 µmol/l, 1μCi/ml) was added and cytochalasin B-sensitive 2-deoxyglucose uptake 
was measured over 10 min (30). 
 
Statistical analysis. Significance of differences was assessed using student’s t test, 1-way or 2-way 
ANOVA as appropriate, using Sidak’s test after ANOVA. Significance is indicated in Figures as 
follows: 
*
P<0.05, 
**
P<0.01, 
***
P<0.001, 
****
P<0.0001 or 
†
P<0.05, 
††
P<0.01, 
†††
P<0.001, 
††††
P<0.0001. 
RESULTS 
 
Canagliflozin and phloretin, but not dapafliglozin, empagliflozin or phlorizin, significantly 
activate AMPK in HEK-293 cells. To assess the impact of canagliflozin on AMPK, we initially 
utilized HEK-293 cells. A daily 300 mg dose of canagliflozin produces a peak plasma concentration in 
humans of around 10 µmol/l (31), so we tested concentrations from 1 to 30 µmol/l. Following incubation 
for 1 hour (Fig. 2A), canagliflozin increased AMPK activity at concentrations from 1-30 
µmol/l, with 10 µmol/l giving a similar activation to that observed with 300 µmol/l A769662 (which 
activates AMPK by direct binding between the and subunits (32)) or berberine (a mitochondrial 
inhibitor  that  activates  AMPK  by  increasing  cellular  AMP:ATP  (19)).  AMPK  activation  by 
Hawley et al Canagliflozin activates AMPK 7 
 
 
canagliflozin, A769662 and berberine was associated with increased phosphorylation of Thr172 on 
AMPK and of the primary AMPK site on ACC (pACC) (Fig. 2A; quantified results shown in Figs. 
S1A/B in Supplementary Data). Fig. 2B shows that the effect of 30 µmol/l canagliflozin was rapid, 
reaching a maximum by 20 minutes. 
Figs. 2C/D compare the effects of canagliflozin, dapafliglozin and empagliflozin. Although both of 
the latter activated AMPK, this required concentrations >30 µmol/l, and even at 100 µmol/l their 
effects were small compared with canagliflozin. Effects on phosphorylation of AMPK and ACC (Figs. 
2F-H, quantified results in Figs. S1C-F) were consistent with this. Since single doses of dapafliglozin 
(20 mg) or empagliflozin (50 mg) produce peak plasma concentrations of only 1-2 µmol/l (33; 34), it 
seems unlikely that these inhibitors would produce significant AMPK activation at normal therapeutic 
doses. 
We also examined the effects of the natural product phlorizin and its aglycone form, phloretin. 
Interestingly, phloretin activated AMPK, and promoted phosphorylation of AMPK and ACC, at 
concentrations slightly higher than canagliflozin. However, phlorizin only affected these parameters 
marginally at much higher concentrations (Figs. 2E/I/J; quantification of blots in Fig. S1G/H). 
 
Canagliflozin activates AMPK by inhibiting Complex I of the respiratory chain. To test whether 
canagliflozin activated AMPK by increasing cellular AMP or ADP, we tested its effects in HEK-293 
cells expressing the wild type AMPK-2 subunit (WT cells) or the AMP/ADP-insensitive R531G 
mutant (RG cells) (19). Canagliflozin activated AMPK and promoted its phosphorylation in WT cells, 
but not in RG cells; similar results were obtained with phloretin (Fig. 3; quantification of blots in Fig. 
S2). These results suggest that canagliflozin and phloretin activate AMPK by increasing cellular AMP 
or ADP. 
Cellular AMP levels are low and difficult to measure in cultured cells, so we routinely measure 
ADP:ATP ratios as a surrogate for AMP:ATP (17). Increasing concentrations of canagliflozin caused 
increases in ADP:ATP ratio that were significant at 10 and 30 µmol/l, with 30 µmol/l canagliflozin 
producing an effect similar to 10 mmol/l phenformin (Fig. 4A). Similar results were obtained with 
phloretin (Fig. 4B). The increase in cellular ADP:ATP due to canagliflozin was accompanied by 
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reduction of cellular oxygen consumption (Fig. 4C); the effect of 30 µmol/l canagliflozin was smaller, 
although more rapid, than that of 10 mmol/l phenformin. When the uncoupler 2,4-dinitrophenol (DNP) 
was added 60 minutes later, in cells treated with DMSO there was a large increase in oxygen 
consumption (representing the maximal respiration rate when mitochondria were not limited by the 
supply of ADP). However, as canagliflozin concentrations increased the effects of DNP were 
eliminated suggesting that, like phenformin, canagliflozin inhibited the respiratory chain rather than the 
F1 ATP synthase. 
We next used primary mouse hepatocytes permeabilised with digitonin, and measured the function 
of respiratory chain Complexes I and II. Fig. 4D and E show that canagliflozin and dapagliflozin 
inhibited Complex I-supported respiration in a concentration-dependent manner, whereas any effect on 
Complex II was marginal. The inhibitory effect of canagliflozin on Complex I was significantly greater 
than that of dapagliflozin, with estimated half-maximal effects at 18 ± 1 µmol/l for canagliflozin and 40 
± 3 µmol/l for dapagliflozin. 
 
AMPK-dependent and –independent effects of canagliflozin on cellular metabolism. To examine 
effects of canagliflozin on metabolic effects mediated by AMPK, we initially used immortalized MEFs 
with a double knockout of AMPK-1 and -2 (DKO), or wild type controls. Fig. 5A shows that 
AMPK was activated by concentrations of canagliflozin above 1 µmol/l in WT cells, associated with 
phosphorylation of AMPK and ACC (blots quantified in Fig. S3A/B). As expected, AMPK activity 
was undetectable in DKO cells, and although ACC expression was normal there was no basal or 
canagliflozin-stimulated ACC phosphorylation. We next measured lipid synthesis using [
14
C]acetate, 
and fatty acid oxidation using [
3
H]palmitate (Figs. 5B/C). A769662 and phenformin (which activate 
AMPK by different mechanisms) caused inhibition of lipid synthesis in the WT cells, while 
canagliflozin caused increasing inhibition at 10 and 30 µmol/l. As expected, the inhibition by A769662 
was abolished in DKO cells but, surprisingly, lipid synthesis was stimulated by both phenformin and 
canagliflozin in DKO cells. Fatty acid oxidation (Fig 5C) was stimulated by AICAR and this was 
abolished in the DKO cells, showing that it was AMPK-dependent. However, phenformin and 
canagliflozin inhibited fatty acid oxidation in both the WT and DKO cells. The explanation for this is 
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likely to be that these drugs, although activating AMPK, inhibit the respiratory chain and therefore 
prevent re-oxidation of NADH and FADH2 generated by fat oxidation, an effect that would be AMPK- 
independent, and that has been observed previously in primary hepatocytes treated with metformin 
(22). 
 
Canagliflozin inhibits lipogenesis in hepatocytes through a mechanism involving phosphorylation 
of ACC by AMPK. The inhibition of lipid synthesis by canagliflozin in Fig. 5B was associated with 
phosphorylation of ACC at the AMPK site(s) (Fig. 5A, results quantified in Fig. S3B). To test whether 
the effect of canagliflozin on lipid synthesis required phosphorylation of ACC1/ACC2, we studied 
hepatocytes from mice with a double knock-in (DKI) of mutations at the AMPK sites on both ACC 
isoforms (22). Fig. 5D shows that increasing concentrations of canagliflozin caused progressive 
inhibition of lipid synthesis in WT hepatocytes that was abolished, at least at concentrations of 10 
µmol/l and below, in DKI cells. The effects of 500 µmol/l metformin were also abolished in the DKI 
cells. However, at 30 µmol/l canagliflozin there was still some inhibition in the DKI cells, although 
significantly less than in WT cells. The effects of canagliflozin and metformin on lipid synthesis were 
accompanied by increased phosphorylation of AMPK and, in WT cells, of ACC. The pACC and total 
ACC antibodies both detected doublets; the lower and upper bands are ACC1 (predicted mass 265 
kDa) and ACC2 (276 kDa) (22). Fig. 5E shows that 10-30 µmol/l canagliflozin significantly increased 
pT172/AMPK-and pACC/ACC (ACC1 + ACC2) in wild type mouse hepatocytes. 
Canagliflozin inhibits glucose uptake in HEK-293 cells and MEFs. We next assessed the effects of 
the drugs on glucose transport by measuring 2-deoxyglucose (2DG) uptake. Canagliflozin inhibited 
uptake by 50-60% in both HEK-293 cells and MEFs, whereas the AMPK activator AICAR had no 
effect. The results were identical in wild type MEFs and AMPK DKO MEFs, showing that this effect 
of canagliflozin was AMPK-independent. We also assessed the expression of SGLT2 in these cell 
types using Western blotting. HEK-293 cells and mouse liver, but not MEFs, expressed a polypeptide 
that co-migrated with SGLT2 in mouse kidney. HEK-293 cells, MEFs and mouse liver also appeared to 
express GLUT1, although the band did not always co-migrate with the bands in control tissue, possibly 
due to variable glycosylation (Fig. 6C). Attempts to measure expression of other glucose transporters 
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(GLUT3, SGLT1) by Western blotting were inconclusive. The effect of canagliflozin to inhibit glucose 
uptake in HEK-293 cells and MEFs appears to be yet another off-target effect, because dapagliflozin 
had no effect on 2DG uptake in either cell type (Fig. 6A/B). To further confirm that the activation of 
AMPK in HEK-293 cells was not secondary to its effects on glucose uptake, we compared the effects 
of canagliflozin with complete glucose removal from the medium (Fig. 6D; quantification of blots in 
Fig. S3C/D). While removal of all glucose caused a modest activation and Thr172 phosphorylation of 
AMPK, activation by 30 µmol/l canagliflozin was >3-fold larger. Since inhibition of glucose uptake by 
canagliflozin was only partial (Fig. 6A), the effect of canagliflozin on AMPK is unlikely to be due to 
reduced supply of glucose for catabolism. 
 
Canagliflozin activates AMPK in mice in vivo. To test whether canagliflozin activated AMPK in 
vivo, it was administered to mice (100 mg/kg) by oral gavage, and 3 hr later tissues were collected by 
freeze clamping in situ, which preserves the activation state of AMPK (35). In liver, Thr172 
phosphorylation of AMPK was significantly increased by this treatment, as was the phosphorylation of 
ACC and Raptor at AMPK sites (Figs. 7A, S4). By contrast, significant increases in phosphorylation of 
AMPK, ACC and Raptor were not observed in muscle (tibialis interior), gonadal white adipose tissue 
or spleen (Fig. S5A-C). We also measured the effects of oral adminstration of canagliflozin, 
administered at the time of withdrawing food from previously fasted mice that had been refed for 2 hr, 
on respiratory exchange ratio (RER). In WT mice canagiflozin caused a more rapid drop in RER than 
vehicle, indicating a more rapid shift back towards fat rather than carbohydrate oxidation (Fig 7B). 
However, this was also observed in ACC1/ACC2 DKI mice, showing that the effect was independent 
of ACC phosphorylation and therefore presumably of AMPK (Fig 7C). This reduction in RER by 
canagliflozin was likely secondary to reduction of blood glucose, which was similar in both WT and 
ACC DKI mice (Fig 7D). 
 
DISCUSSION 
 
Recent clinical trials suggest that the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin 
show promise for reversal of hyperglycemia, either as monotherapy or as adjuncts to existing therapy. 
Compared with dapagliflozin, canagliflozin also has consistently favorable effects on plasma lipid 
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profiles (7; 8; 36; 37). These differential effects on plasma lipids prompted us to investigate whether 
canagliflozin might have SGLT2-independent effects. Our results show that canagliflozin causes a 
substantial activation of AMPK in both human and mouse cells, at concentrations corresponding to the 
peak plasma concentrations achieved following therapeutic doses in humans. By contrast, dapagliflozin 
and empagliflozin only caused a modest AMPK activation at concentrations well above their peak 
plasma concentrations. Thus, activation of AMPK by dapagliflozin or empagliflozin is less likely to be 
significant in vivo. 
Our results demonstrate that AMPK activation is primarily due to inhibition of Complex I of the 
respiratory chain, leading to increases in cellular AMP/ADP that bind to the  subunit and promote 
Thr172 phosphorylation. Thus, canagliflozin: (i) increased cellular ADP:ATP ratios; (ii) increased 
AMPK activation and Thr172 phosphorylation in cells expressing the wild type but not the AMP/ADP- 
insensitive R531G mutant of AMPK-2; (iii) inhibited oxygen uptake in HEK-293 cells; (iv) inhibited 
oxygen uptake in permeabilized mouse hepatocytes provided with substrates that feed into complex I. 
Dapagliflozin also caused a less potent effect on Complex I, although only at concentrations (10-30 
µmol/l) higher than those observed in human plasma with normal doses. We also found that 
canagliflozin, but not dapagliflozin, inhibited 2-deoxyglucose uptake in HEK-293 cells and MEFs in an 
AMPK-independent manner, indicating that it had additional off-target effects on glucose transport, 
presumably due to inhibition of another glucose tranporter such as GLUT1. Indeed, previous studies in 
L6 myotubes have indicated that 10 mol/l canagliflozin can inhibit glucose uptake by approximately 
50%, an effect that was attributed to GLUT1 inhibition (38). However, this is unlikely to account for 
the AMPK activation observed in our experiments, because even complete removal of glucose from the 
medium had only a modest effect on AMPK activity compared to canagliflozin. 
Interestingly, we found that the aglycone derivative of phlorizin, phloretin, also activated AMPK, 
although phlorizin itself was much less effective. Like canagliflozin, phloretin appeared to act by 
increasing cellular AMP. Both phlorizin (39) and phloretin (40) were reported previously to inhibit the 
function of isolated mitochondria, but we found that only phloretin is effective in intact cells, perhaps 
due to greater membrane permeability. 
Our studies also show that AMPK activation has the expected effects on lipid synthesis in intact 
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cells. Thus, three distinct AMPK activators, A769662, phenformin and canagliflozin, all inhibited the 
pathway in MEFs, and these inhibitory effects were abolished in MEFs lacking AMPK, correlating 
with a complete loss of ACC phosphorylation. Surprisingly, phenformin and canagliflozin (but not 
A769662) stimulated lipid synthesis in DKO cells. When we measured fatty acid oxidation in the same 
cells, phenformin and canagliflozin inhibited the pathway in an AMPK-independent manner, which is 
expected since both compounds inhibit Complex I. The major fates of cellular acetyl-CoA are oxidation 
by the TCA cycle or incorporation into lipids. Thus, in the absence of AMPK to inhibit lipid synthesis, 
acetate flux might be diverted into lipid synthesis as oxidation was inhibited. This provides an 
explanation for the paradoxical activation of lipid synthesis by phenformin and canagliflozin observed 
in AMPK knockout cells. 
Our results in isolated mouse hepatocytes demonstrate that the effects of canagliflozin on lipid 
synthesis are mediated by phosphorylation of ACC. Thus, a moderate and therapeutically relevant 
concentration of canagliflozin (10 µmol/l) inhibited lipid synthesis in WT hepatocytes, but failed to do 
so in DKI cells from mice where both ACC isoforms lacked the critical AMPK site. At higher 
canagliflozin (30 µmol/l) there was some inhibition even in DKI hepatocytes, although significantly 
less than in WT cells; this is most likely because both ACC isoforms use ATP as a direct substrate. 
Once the increase in cellular ADP:ATP ratio becomes substantial, as with 30 µmol/l canagliflozin (Fig. 
4A), decreases in ATP may limit flux through ACC independently of AMPK. This is a revealing 
demonstration of the physiological role of AMPK: as ATP falls under situations of energetic stress the 
kinase limits the function of energy-consuming pathways before the ATP concentration has dropped to 
levels where it becomes limiting for the pathway itself. This occurs because AMPK is more sensitive to 
ATP depletion than the ATP-consuming enzymes in the pathway. 
Our results show that oral administration of canagliflozin increased Thr172 phosphorylation of 
AMPK in liver in vivo, as well as phosphorylation of two of its well-recognized downstream targets, 
ACC and Raptor. Although we only tested effects of the drug in normal mice, there is no reason to 
believe the results would be any different in diabetic models. For example, berberine (which activates 
AMPK by the same mechanism as cangliflozin (19)) activates AMPK normally in db/db mice (42). 
Canagliflozin also caused a more rapid drop in respiratory exchange ratio when administered to fed 
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mice, indicating a more rapid switch to fat versus carbohydrate oxidation. However, this was still 
observed in the DKI mice, and was therefore presumably independent of AMPK. It is possible that a 
reduction in blood glucose caused by canagliflozin causes increased fat oxidation due to competition 
between glucose and fat for substrate oxidation (41), and that this obscures any effect due to ACC 
phosphorylation by AMPK; this might be addressed in future studies using SGLT2 knockout mice. 
Our findings raise the interesting question as to whether dual therapy with canagliflozin and 
metformin would be more effective than canagliflozin alone. In a recently reported clinical trial of 
newly diagnosed subjects with type 2 diabetes (43), monotherapy with canagliflozin was found to be 
more effective in lowering HBA1C than metformin. Although dual therapy was more efficacious than 
canagliflozin alone, the effects of the two drugs were not additive, as might be expected if they had 
distinct mechanisms of action. By contrast, in a similar trial using metformin and dapagliflozin, 
monotherapy with dapagliflozin was not more effective than metformin, and the effects of dual therapy 
were closer to being additive (44). 
Finally, although the long-term effects of metformin to inhibit hepatic glucose production in mice 
are AMPK-dependent (22), studies have suggested that its rapid effects are AMPK-independent (20; 
21). However, the latter authors agree that the primary effect of metformin is to inhibit the respiratory 
chain and increase cellular AMP in the liver, which is then proposed to affect other AMP-sensitive 
targets such as fructose-1,6-bisphosphatase (20) or adenylate cyclase (21). Since canagliflozin inhibits 
the respiratory chain and activates AMPK in liver, it is conceivable that these AMP-dependent, but 
AMPK-independent, effects of metformin might also be mimicked by canagliflozin. 
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FIGURE LEGENDS 
Figure 1:   Structures of compounds used in this paper. 
 
Figure 2: AMPK activation in HEK-293 cells by canagliflozin and other SGLT2 inhibitors. (A) 
HEK-293 cells were treated for 1 hr with the indicated concentrations of canagliflozin, or 
A769662 or berberine as positive controls. The upper panel shows kinase assays of 
immunoprecipitates prepared using anti-pan antibodies (mean ± SD, n = 2). The lower 
panel shows analysis of AMPK and ACC phosphorylation by Western blotting from 
duplicate dishes of cells. (B) Time course of AMPK activation by 30 µmol/l canagliflozin 
(mean ± SD, n = 2). (C) Comparison of effects of canagliflozin and dapagliflozin (1 hr 
incubations, mean ± SEM, n = 4; significance of differences from DMSO controls 
indicated). (D) Comparison of effects of canagliflozin and empagliflozin, as in (C). (E) 
Comparison of effects of phloretin and phlorizin, as in (C). (F)-(J) Phosphorylation of 
AMPK and ACC in duplicate wells in response to: (F) canagliflozin (from experiment in 
2C); (G) dapagliflozin, from experiment in 2C; (H) empagliflozin, from experiment in 2D; 
(I) phloretin, from experiment in 2E; (J) phlorizin, from experiment in 2E. See Fig. S1 in 
Supplementary data for quantification of these blots. 
Figure 3:   Comparison of AMPK activation by canagliflozin and phloretin in WT and RG cells. 
(A) WT and RG HEK-293 cells were treated for 1 hr with the indicated concentrations of 
canagliflozin, and the results of kinase assays in anti- immunoprecipitates are shown 
(mean ± SEM, n = 4 to 6). Significance of differences from vehicle control are indicated. 
(B) Analysis of AMPK phosphorylation in duplicate dishes of cells from the same 
experiment as in (A). (C) As (A), but using phloretin. (D) As (B), but using phloretin. See 
Fig. S2 in Supplementary data for quantification of these blots. 
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Figure 4: Effects of canagliflozin, phloretin and phenformin on cellular ADP:ATP ratios and 
oxygen uptake. (A) Effects of phenformin and increasing concentrations of canagliflozin 
on cellular ADP:ATP ratios. HEK-293 cells were treated with the indicated drug 
concentration for 1 hr and cellular ADP:ATP ratios determined by capillary electrophoresis 
of perchloric acid extracts (mean ± SEM, n = 4). Significances of differences from vehicle 
control are indicated. (B) As (A), but using phloretin in place of canagliflozin. (C) Effects 
of phenformin and increasing concentrations of canagliflozin on cellular oxygen uptake. At 
the point shown by the first arrow (“drug”) vehicle (DMSO), phenformin (10 mmol/l) or 
the indicated concentration of canagliflozin (µmol/l) was added and oxygen uptake then 
measured at regular intervals. At the point shown by the second arrow (“DNP”) 2- 
dinitrophenol was added and oxygen uptake measured for a further 15 min. Results are 
expressed as % of the mean of the first 3 time points prior to drug addition (mean ± SD, 3 
replicate dishes performed twice, n = 6). After addition of drugs, the effects of 10 µmol/l 
canagliflozin were significantly different from the DMSO control by 2-Way ANOVA 
(Dunnett’s multiple comparison test) at all time points except 67.5 and 75 min; effects of 
30 µMOL/L canagliflozin and 10 mmol/l phenformin were significant at all time points. 
(D)-(E) Complex  I  and  II-supported  respiration  in  permeabilized  primary  mouse 
hepatocytes. The cells were permeabilized with digitonin and then provided with ADP and 
glutamate and malate to stimulate Complex I-supported respiration, or rotenone, succinate 
and ADP to simulate Complex II-supported respiration. Results are expressed as percent 
inhibition of Complex I and II by canagliflozin and dapagliflozin (mean ± SEM, n = 3-5). 
Statistically significant differences between effects of canagliflozin and dapagliflozin by 2- 
way ANOVA are indicated. 
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Figure 5: Effects of canagliflozin on AMPK, lipid synthesis and fatty acid oxidation in intact 
cells. (A) Wild type and AMPK-1-/- 2-/- MEFs (AMPK-1/2 DKO) were incubated 
with the indicated concentrations of canagliflozin for 1 hr and AMPK activity determined 
(upper panel) in anti-AMPK- immunoprecipitates (mean ± SEM, n = 4; assays were 
performed in the DKO cells although the activity, as expected, was negligible). 
Significance of differences from the vehicle control are indicated. The lower panel shows 
phosphorylation of AMPK and ACC analyzed in duplicate dishes of cells from the same 
experiment: see Fig. S3 in Supplementary data for quantification of these blots. (B) Lipid 
synthesis (incorporation of radioactivity from [
14
C]acetate into total lipid, i.e. fatty acids 
and sterols) in wild type and AMPK-1/2 DKO MEFs incubated in the indicated 
concentrations of A769662, phenformin or canagliflozin for 1 hr (mean ± SEM, n = 4). 
Significance of differences from vehicle controls are indicated. (C) Fatty acid oxidation 
(incorporation of radioactivity from [
3
H]palmitate into 
3
H2O) in wild type and AMPK- 
1/2 DKO MEFs incubated in the indicated concentrations of phenformin, AICAR or 
canagliflozin for 1 hr. Results are mean ± SEM, n = 4; significance of differences from 
vehicle controls are indicated. (D) Lipid synthesis and protein phosphorylation in primary 
mouse hepatocytes from wild type and ACC1/ACC2 DKI mice. The upper panel shows 
incorporation of radioactivity from [
3
H]acetate into total lipid measured after 4 hr (mean ± 
SEM, cells from 3 mice, each performed in triplicate). Significant differences from control 
within each genotype (
****
P<0.0001) and between genotypes at the same drug concentration 
(
†
P<0.05, 
††
P<0.01, 
††††
P<0.0001) are indicated. The lower panel shows analysis of 
protein phosphorylation by Western blotting of a representative example. (E) 
Quantification of the increases in phosphorylation in wild type hepatocytes of Thr172 on 
AMPK (left) or Ser79 plus Ser212 on ACC1/ACC2 (right), normalized for the expression 
of total AMPK or ACC1/ACC2 and expressed relative to control (mean ± SEM, n = 4 for 
pT172/AMPK-and n = 5 for pACC/ACC). Significant differences from vehicle controls 
are indicated. 
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Figure 6: Canagliflozin inhibits glucose transport  in HEK-293 cells and MEFs, but this does 
not account for AMPK activation. (A) Uptake of 2-deoxyglucose (2DG) in HEK-293 
cells treated with 10 µmol/l canagliflozin, 10 µmol/l dapagliflozin or 1 mmol/l AICAR. 
Results are mean ± SEM (n = 5); significance of differences from vehicle controls are 
indicated. (B) As (A), but in wild type or AMPK-1-/-/2-/- (DKO) MEFs. (C) Expression 
of SGLT2 and GLUT1; membrane fractions from MEFs or HEK-293 cells (80 µg protein), 
mouse kidney or liver (30 µg), mouse brain (15 µg) or human placenta (7.5 µg) were 
analysed by Western blotting and probed using the indicated antibodies. (D) Effect of total 
removal of medium glucose (centre) or 30 µmol/l canagliflozin (right) on AMPK activity 
(top) and phosphorylation of AMPK (pT172) and ACC (pACC). Results in the bar chart are 
mean ± SEM (n = 3); statistical significance of differences are indicated. 
Figure 7: Liver AMPK is activated by oral adminstration of canagliflozin in mice, but this does 
not explain changes in respiratory exchange ratio. (A) Phosphorylation of AMPK, ACC 
and Raptor relative to total protein in mouse liver after oral administration of canagliflozin 
(100 mg/kg) to mice.(mean ± SEM, n = 9-11, significance of differences by Student’s t test 
indicated). (B) Respiratory exchange ratio (CO2/O2) in 12 hr fasted mice that had been 
refed a carbohydrate-rich diet for 2 hrs between 7 and 9 am (black bars) and were then 
administered vehicle) or canagliflozin (30 mg/kg) at the time that food was withdrawn 
again. Results are mean ± SEM, n = 10-12. (C) As (B), but experiments performed in 
ACC1/ACC2 DKI mice; results are mean ± SEM, n = 5-7. (D) Glucose concentrations in 
the tail vein during experiments of the type shown in Figs. 7B/C. Statistically significant 
differences in canagliflozin samples versus vehicle control are indicated. 
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A) Effect of canagliflozin on cellular ADP:ATP ratios B) Effect of phloretin on cellular ADP:ATP ratios 
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C) Effects on cellular O2 uptake (HEK-293 cells) D) Effects on Complex I (mouse hepatocytes) 
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D) Effects on Complex II (mouse hepatocytes) 
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A) AMPK activation by canagliflozin in mouse embryo fibroblasts 
 
**** 
 
300 
 
B) Lipid synthesis from [14C]acetate in mouse embryo fibroblasts 
 
 
150 
 
200 
 
 
100       
 
 
 *  
 
**** 100 
 
 
50 
 
pT172 
AMPK- 
pACC 
A769662 (300 µM): + + 
phenformin (3 mM): +  + 
canagliflozin (10 µM):  +  + 
ACC 
Canagliflozin (µM):   0 1 3 10 30 0 1 3 10 30 
canagliflozin (30 µM): + + 
WILD TYPE AMPK-1/2 DKO 
WILD TYPE AMPK-1/2 DKO 
C) Oxidation of [3H]palmitate in mouse embryo fibroblasts D) Lipogenesis and phosphorylation in WT and DKI hepatocytes 
150 
100       
50 
**** 
 
 
 
 
 
 
 
 
 
 
**** 
 
 
 
 
 
 
 
 
**** 
**** 
 
 
 
 
 
 
 
 
 
 
 
**** 
 
 
 
 
 
 
 
 
 
**** 
 
 
 
120 
100               
80 
60 
40 
20 
 
 
 
 
 
 
**** 
 
 
 
 
 
 
 
 
 
**** 
 
 
 
 
 
 
 
**** 
 
† †† 
 
 
 
†††† 
 
 
 
 
 
 
 
†† 
**** 
 
 
†††† 
AICAR (1 mM): + + 
phenformin (3 mM): +  + 
canagliflozin (30 µM):  +  + 
 
WILD TYPE AMPK-1/2 DKO 
 
E) Quantification of protein phosphorylation in WT hepatocytes 
 
pT172 
AMPK-
pACC    
ACC    
canagliflozin (µM):   0 1 
 
 
 
 
 
 
 
 
3 10   30 
 
 
 
 
 
 
 
 
0 1 3 
 
 
 
 
 
 
 
 
10   30 
4 
metformin (µM): 500 500 
WILD TYPE ACC1/ACC2 DKI 
3 
 
2 
 
1 
 
 
canagliflozin (µM): 0 1 3    10 30 0 1 3 10   30  
metformin (µM):  500  500 
  
**** **** 
** 
** 
****   **** 
**** 
P
-p
ro
te
in
/t
o
ta
l 
p
ro
te
in
 
(r
e
la
ti
v
e
 t
o
 c
o
n
tr
o
l)
 
P
a
lm
it
a
te
 o
x
id
a
tio
n
 
(%
 c
o
n
tr
o
l)
 
A
M
P
K
 a
ct
iv
ity
 
(%
 c
o
n
tr
o
l)
 
L
Ip
id
 s
y
n
th
e
s
is
 
(%
 c
o
n
tr
o
l)
 
L
Ip
id
 s
y
n
th
e
s
is
 
(%
 c
o
n
tr
o
l)
 
Hawley et al (Figure 6) 
 
** ** 
* 
 
 
A) 2-Deoxyglucose uptake (HEK-293) B) 2-Deoxyglucose uptake (MEFs) 
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A) Phosphorylation in liver after canagliflozin treatment in vivo 
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protein kinase by inhibiting mitochondrial function and increasing cellular AMP 
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SUPPLEMENTARY DATA 
 
 
This file contains Figure legends for Supplementary Figure S1-S5 
 FIGURE LEGENDS 
Figure S1: Quantification of Western blots from Fig. 2. The Western blots were subject to 
densitometry on the Li-Cor Odyssey IR scanner and the results are presented as ratios 
(± SD, n = 2) of signals obtained with anti-pT172 to total AMPK-, or with pACC to 
total ACC. 
Figure S2: Quantification of Western blots from Fig. 2. Results expressed as ratios (± SD, n = 
2) of signals obtained with anti-pT172 to total AMPK-as in Fig. S1. 
 
Figure S3: Quantification of Western blots from Figs. 5 and 6. Results expressed as ratios (± 
SD, n = 2) of signals obtained with anti-pT172 to total AMPK-, or with pACC to 
total ACC, as in Fig. S1. 
Figure S4: Representative Western blots from which the data in Fig. 7A were generated. 
 
Figure S5: Canagliflozin does not activate AMPK in mouse muscle, white adipose tissue or 
spleen in vivo. Samples were from the same experiment as in Fig. 7A but were from: 
(A) skeletal muscle (tibialis anterior, mean ± SEM, n = 5-11); (B) white adipose tissue 
(mean ± SEM, n = 4-12). (C) spleen (mean ± SEM, n = 7-10); ns, not significant. 
Hawley et al (Figure S1) 
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A) Fig. 3B (pT172:AMPK-) B) Fig. 3D (pT172:AMPK-) 
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A) Fig. 5A (pT172:AMPK-) B) Fig. 5A (pACC:ACC) 
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A) Phosphorylation in muscle (tibialis anterior) after canagliflozin treatment in vivo 
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